Australian Clinical Labs (ACL) H1 2025 earnings summary

Executive summary

• Revenue for H1 FY25 reached $369.2 million, up 9.5% year-over-year, with underlying EBIT of $27.3 million, a 17% increase, and EBIT margin at 7.4%.

• Underlying NPAT rose 18% to $12.1 million; statutory NPAT increased to $11.8 million year-over-year.

• Interim fully franked dividend of 3.5 cents per share declared, representing 59% of underlying NPAT.

• Free cash flow before interest, tax, and financing was $26.8 million, with cash conversion at 98%.

• On-market share buyback of $4.4 million completed, with 1.3 million shares repurchased.

Financial highlights

• Revenue grew 9.5% year-over-year to $369.2 million; underlying EBITDA increased 9% to $95.1 million.

• Underlying EBIT margin improved by 50bps to 7.4%; free cash flow conversion from underlying EBIT at 98%.

• Net debt (excluding lease liabilities) stood at $34.2 million; borrowings remained flat.

• Operating cash flow for the half-year was $81.1 million, up from $73.5 million in the prior period.

• Interim dividend of 3.5 cents per share declared, up from 3.0 cents in the prior year.

Outlook and guidance

• FY25 underlying EBIT guidance reconfirmed at $65–73 million, with H2 EBIT margin expected to return to low double digits due to seasonality.

• Short-term margin pressure expected from inflation and below-trend market volumes; 2H FY25 started with lower volume growth (2.9%).

• Ongoing focus on operational efficiency, private billing, and digitization projects to drive future growth.

• Directors are not aware of any subsequent events that may significantly affect future operations.

• The Group is considered able to pay its debts as they fall due, with accounts prepared on a going concern basis.